NextMed has said that it expects an update on its new drug submission (NDS) for Vitaros, its topical treatment for erectile dysfunction, within the next 30 days.

The company said that it had been advised that Health Canada, the Canadian government department responsible for public health, is still reviewing its response for acceptance.

An acceptance of the response is expected to trigger a new, 150-day review cycle by the NDS reviewers for a final approval or rejection of the marketing application.